Drug Safety Alert
Update from WHO Global Surveillance and Monitoring System
|Date:||12th of October 2022.|
|Target Audience:||• Healthcare Professionals- Physicians, Pharmacists, and Nurses.|
• Manufacturers and Importers of Glycerin containing formulations to control level of Diethylene glycol and Ethylene glycol
• General Public
|Problem or Issue:||World Health Organization (WHO) has issued Medical Product Alert No. N°6/2022 dated 05th October 2022 which refers to four substandard products, identified in Gambia. These four products are Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup. Laboratory analysis of samples of each of the four products confirm that they contain unacceptable amounts of diethylene glycol and ethylene glycol as contaminants.|
DRAP has never authorized sale of any products from Maiden Pharmaceuticals Limited (Haryana, India) and these four products referred in WHO medical product alert are neither registered nor available on Pakistan market, however these may have been carried for personal use while visiting other countries. Please do not use any of these products as these are substandard products and their use may result in serious injury.
|Potential Hazards linked to DEG and EG:||Toxic effects can include abdominal pain, diarrhea, inability to pass urine, headache, altered mental state, vomiting and acute kidney injury which may lead to death especially in children|
|Advice for healthcare professionals:||DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities to detect any substandard / falsified product in the market. Adverse reactions or quality problems experienced with the use of any product shall be reported to the National Pharmacovigilance Centre(NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information of reporting problems to DRAP is available on this link.|
|Advice for Manufacturer’s and Importers of Products containing Glycerin Solvent:||Unacceptable amounts of Diethylene glycol (DEG) and Ethylene glycol (EG) as contaminants may lead to severe injury or death. You are therefore advised to strictly follow the pharmacopoeia guidelines for excipients and ensure testing of all those products where diethylene glycol and ethylene glycol can appear as impurity, to ensure specifications limits are being comply for all those products where glycerin is used especially cough syrups and other oral products.|
|Advice for General Public:||All therapeutic goods must be obtained from the licensed pharmacies, and other authorized retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professional in case of any doubt.|
|Guidelines for reporting Adverse Drug Reactions (ADRs):||Both healthcare professionals and patients are requested to report any adverse events they have experienced to the National Pharmacovigilance Centre, Drug Regulatory Authority of Pakistan through DRAP Med Vigilance E-reporting system or at firstname.lastname@example.org.|
Similarly, adverse events can also be reported through Med Safety Mobile Application that is available for download from the App store (For iOS devices) and Google Play (For Android devices).
|References:||Medical Product Alert No. N°6/2022|